These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

276 related articles for article (PubMed ID: 20056235)

  • 21. Cytotoxic and genotoxic monitoring of sickle cell anaemia patients treated with hydroxyurea.
    Khayat AS; Antunes LM; GuimarĂ£es AC; Bahia MO; Lemos JA; Cabral IR; Lima PD; Amorim MI; Cardoso PC; Smith MA; Santos RA; Burbano RR
    Clin Exp Med; 2006 Mar; 6(1):33-7. PubMed ID: 16550342
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A pilot study of electronic directly observed therapy to improve hydroxyurea adherence in pediatric patients with sickle-cell disease.
    Creary SE; Gladwin MT; Byrne M; Hildesheim M; Krishnamurti L
    Pediatr Blood Cancer; 2014 Jun; 61(6):1068-73. PubMed ID: 24436121
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effects of hydroxyurea in a population of Brazilian patients with sickle cell anemia.
    Vicari P; Barretto de Mello A; Figueiredo MS
    Am J Hematol; 2005 Mar; 78(3):243-4. PubMed ID: 15726590
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Treating sickle cell anaemia with hydroxycarbamide.
    Pollack S
    Br J Haematol; 2014 Jan; 164(2):296-7. PubMed ID: 24116862
    [No Abstract]   [Full Text] [Related]  

  • 25. Hydroxyurea for sickle-cell anaemia in Africa: mind the gap.
    Obaro SK
    Lancet Glob Health; 2015 Mar; 3(3):e124-5. PubMed ID: 25701988
    [No Abstract]   [Full Text] [Related]  

  • 26. [Effect of hydroxyurea on hemoglobin S].
    Torres AF; Eberle SE; Sciuccati G; Bonduel M
    Medicina (B Aires); 2003; 63(2):140-2. PubMed ID: 12793083
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Long-term use of hydroxyurea for sickle cell anemia.
    Lee DA; Mueller BU
    JAMA; 2003 Aug; 290(6):753-4; author reply 754. PubMed ID: 12915425
    [No Abstract]   [Full Text] [Related]  

  • 28. Reduction of the clinical severity of sickle cell/beta-thalassemia with hydroxyurea: the experience of a single center in Greece.
    Loukopoulos D; Voskaridou E; Kalotychou V; Schina M; Loutradi A; Theodoropoulos I
    Blood Cells Mol Dis; 2000 Oct; 26(5):453-66. PubMed ID: 11112383
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Long-term use of hydroxyurea for sickle cell anemia.
    Feldman L; Allen S; Westerman M; Feldman L; Gilman-Sachs A; Beaman K
    JAMA; 2003 Aug; 290(6):752-3; author reply 754. PubMed ID: 12915423
    [No Abstract]   [Full Text] [Related]  

  • 30. [From Hemoglobin SS to SF: interest of hydroxyurea in the management of sickle cell disease in two Congolese children and review of the literature].
    Nkashama GM; Wakamb GK; Mulangu AM; Nkashama GM; Kupa BK; Numbi OL
    Pan Afr Med J; 2015; 21():124. PubMed ID: 26327961
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Long-term use of hydroxyurea for sickle cell anemia.
    Hagar W
    JAMA; 2003 Aug; 290(6):753; author reply 754. PubMed ID: 12915424
    [No Abstract]   [Full Text] [Related]  

  • 32. Hydroxyurea and sickle cell disease: a chance for every patient.
    Weiner DL; Brugnara C
    JAMA; 2003 Apr; 289(13):1692-4. PubMed ID: 12672739
    [No Abstract]   [Full Text] [Related]  

  • 33. Hydroxyurea in sickle cell disease patients from Eastern Saudi Arabia.
    Al-Jam'a AH; Al-Dabbous IA
    Saudi Med J; 2002 Mar; 23(3):277-81. PubMed ID: 11938415
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Exposure to hydroxyurea during pregnancy in sickle-beta thalassemia: a report of 2 cases.
    Italia KY; Jijina FF; Chandrakala S; Nadkarni AH; Sawant P; Ghosh K; Colah RB
    J Clin Pharmacol; 2010 Feb; 50(2):231-4. PubMed ID: 19797538
    [No Abstract]   [Full Text] [Related]  

  • 35. Monitoring toxicity, impact, and adherence of hydroxyurea in children with sickle cell disease.
    Brandow AM; Panepinto JA
    Am J Hematol; 2011 Sep; 86(9):804-6. PubMed ID: 21815183
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Principles and indications of chronic transfusion therapy for children with sickle cell disease.
    Ware R
    Clin Adv Hematol Oncol; 2007 Sep; 5(9):686-8. PubMed ID: 17982409
    [No Abstract]   [Full Text] [Related]  

  • 37. [Hydroxyurea and other agents stimulating synthesis of fetal hemoglobin].
    de Montalembert M
    Pathol Biol (Paris); 1999 Jan; 47(1):55-8. PubMed ID: 10081780
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Hydroxyurea marketed for sickle cell anemia.
    Am J Health Syst Pharm; 1998 May; 55(9):875. PubMed ID: 9588244
    [No Abstract]   [Full Text] [Related]  

  • 39. Management of sickle cell disease.
    Steinberg MH
    N Engl J Med; 1999 Apr; 340(13):1021-30. PubMed ID: 10099145
    [No Abstract]   [Full Text] [Related]  

  • 40. Expanding the role of hydroxyurea in children with sickle cell disease.
    Rogers ZR; Buchanan GR
    J Pediatr; 2004 Sep; 145(3):287-8. PubMed ID: 15343174
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.